Search

Your search keyword '"Han, J-Y."' showing total 2,652 results

Search Constraints

Start Over You searched for: Author "Han, J-Y." Remove constraint Author: "Han, J-Y."
2,652 results on '"Han, J-Y."'

Search Results

156. Measurement of the charge asymmetry of electrons from the decays of W bosons produced in pp̅ collisions at √s =1.96 TeV

157. Measurement of the charge asymmetry of electrons from the decays of W bosons produced in p p ¯ collisions at s =1.96 TeV MEASUREMENT of the CHARGE ASYMMETRY of ELECTRONS ... T. AALTONEN et al

158. Measurement of the charge asymmetry of electrons from the decays of W bosons produced in $\overline{pp}$ collisions at $\sqrt{s}$ =1.96 TeV

159. Search for scalar top quark production in $ \sqrt{s}=1.96\;\mathrm{TeV} $

161. 1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03

162. 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A

164. Improved determination of the sample composition of dimuon events produced in $\sqrt{s}=1.96$ TeV

165. Comments and Reply on: “Study of multi-muon events produced in $\sqrt{s}=1.96$ TeV”; T. Aaltonen et al. (The CDF Collaboration)

166. Study of multi-muon events produced in $\sqrt{s}=1.96$ TeV

169. Search for narrow resonances lighter than ϒ mesons

173. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial

174. Capmatinib (INC280) in patients (pts) with METex14-mutated advances NSCLC: an update from phase 2 GEOMETRY mono-1 study

175. Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study

176. Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study

177. Neutron measurements from antineutrino hydrocarbon reactions

178. Tumour necrosis factor [alpha] signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice

179. OFP01.03 Systemic and Intracranial Efficacy of Brigatinib vs.Crizotinib: Updated Results from the ALTA-1L Trial

182. 383MO Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping

Catalog

Books, media, physical & digital resources